QINGSONG HEALTH (02661) signs a strategic cooperation memorandum with Basel Medical to achieve mutual development in technology output and technological iteration.

QINGSONG HEALTH (02661) announced that on June 10, 2026, the company and Basel Medical Group Limited (Basel Medical, NASDAQ stock code: BMGL) reached a three-year strategic cooperation memorandum through friendly negotiations. This collaboration will leverage the group's self-developed MedClaw medical AI collaborative body system and AIcare technology stack advantages, as well as years of experience in the AI health field, to achieve mutual technological output and development. Both parties believe that combining the group's verified health AI infrastructure with Basel Medical's clinical scenarios and market access in Southeast Asia will help promote the intelligent upgrading of regional medical services and explore new market opportunities together. Based on the group's Alcare technology stack, both parties plan to support Basel Medical in Southeast Asia to carry out AI-native medical service upgrades and jointly expand the regional market, establishing a long-term and stable strategic partnership.